We are offering high quality of Ropinirol Hydrochloride. We are known for manufacturing, exporting, Distributing, trading and supplying Ropinirol Hydrochloride in Gujarat, India. Further, this is safely Packaged by our professionals in diverse packaging options that maintain its purity and Effectiveness. Shreeji Pharma International is leading Manufacturer, Exporter, Distributor, and Supplier of Ropinirol Hydrochloride in Gujarat. India. Shreeji Pharma International manufacturing & supplying all products under GMP site with all types of regulatory supports.
Shreeji Pharma International is the largest manufacturer, Exporter and supplier of Ropinirol Hydrochloride Nowadays Shreeji Pharma International is one of the leading manufacturer and exporter, who is manufacturing Ropinirol Hydrochloride as well as Intermediates of Ropinirol Hydrochloride.
Shreeji Pharma International is exporter, supplier, distributor and manufacturers of the Active Pharmaceuticals Ingredients in many countries for many years.
Shreeji Pharma International currently export Ropinirol Hydrochloride to countries like Gulf Countries,South East Asia countries, African Countries, CIS Countries, LATAM countries, Central American Countries and in European countries
Ropinirole Hydrochloride is a synthetic non-ergoline dopamine agonist primarily used in the treatment of Parkinsons disease and Restless Legs Syndrome (RLS). It mimics the action of dopamine in the brain, which is typically deficient in patients suffering from these conditions. By stimulating dopamine D2 and D3 receptors, ropinirole helps to improve motor control and reduce symptoms associated with dopamine deficiency.
Structure:
Physical and Chemical Properties
Mechanism of Action:Ropinirole binds selectively to dopamine D2-like receptors (D2 and D3) and acts as an agonist. It stimulates these receptors in the striatum and substantia nigra, improving dopaminergic transmission in patients with Parkinsons disease.
Absorption:Rapidly absorbed from the gastrointestinal tract with a bioavailability of 55%. Peak plasma concentrations (Tmax) occur within 12 hours for immediate-release formulations.
Half-life:Approximately 6 hours (immediate-release); prolonged in extended-release forms.
Metabolism:Extensively metabolized in the liver by cytochrome P450 enzyme CYP1A2.
Elimination:Excreted primarily in the urine as inactive metabolites.
Clinical Uses
Price: